SALT LAKE CITY/PRNewswire/ — Amedica
Corporation, a spinal and reconstructive implant and instrument
manufacturer announced today that it will begin distribution of Dynamic Bone, a
unique expandable allograft bone provided by Dynamic Surgical Solutions and
BioDfence™ DryFlex, an easy to handle, flexible amniotic membrane manufactured
by BioDlogics. These new allograft products provide surgeons with innovative
solutions for their patients and expand the Origin® Orthobiologics line of
products.
Dynamic Bone is customized, compressed, demineralized
cancellous bone that expands like a sponge upon hydration. As an
osteoconductive material, Dynamic Bone is ideally suited for spinal fusion
procedures, and can be hydrated with osteoinductive liquids such as bone marrow
aspirate, bone morphogenic proteins, or other viable tissue matrix products
such as BioDfactor™, which is already offered through Amedica. What makes
Dynamic Bone unique is that after placement within the vertebral body it
continues to expand, filling any open cavity for a custom press-fit which will
help match each patient’s anatomy, and may ultimately improve overall fusion
rates.
BioDfence DryFlex is a resorbable adhesion barrier derived
from amniotic membrane procured from live, healthy donors during childbirth. It
can be used as a physical barrier between the dura and surrounding soft tissue
to reduce the potential for post-operative complications due to scar tissue. The
DryFlex strength and flexibility make it ideally suited for MIS procedures.
“Both Dynamic Bone and BioDfence DryFlex provide some
of the most advanced biologic technologies available today, and address
surgeons’ need to improve spinal outcomes,” stated Eric Olson, President
and CEO of Amedica. “By adding these two products to our best-in-class
orthobiologics portfolio, we expect to drive enhanced revenue growth and company
value creation. Amedica has a strong track record of successfully launching new
biologic products and we expect to realize the benefits of these products in
both top-line growth and shareholder value over the long-term. However, the
bottom line is that we believe this will help the company reach our ultimate
goal of assisting our surgeon customers in improving patient outcomes in an
innovative, cost-effective manner,” Olson concluded.
Additional information about the Company’s complete line of
products may be found at www.amedica.com.
